Human Molecular Genetics, Vol 7, 1083-1090, Copyright © 1998 by Oxford University Press
MG Dunckley, M Manoharan, P Villiet, IC Eperon and G Dickson
Deletions and point mutations in the gene encoding the cytoskeletal protein
dystrophin and its isoforms cause either the severe progressive myopathy
Duchenne muscular dystrophy (DMD) or the milder Becker muscular dystrophy
(BMD), largely depending on whether the reading frame is lost or maintained
respectively. Frameshift mutations tend to result in a lack of dystrophin
at the sarcolemma, destabilization of the membrane and degeneration of
skeletal muscle. The mdx mouse is a valuable animal model of DMD as it
bears a nonsense point mutation in exon 23 of the murine DMD gene leading
to an absence of dystrophin expression in the muscle sarcolemma and
muscular dystrophy. This report represents a novel approach to correct
dystrophin deficiency at the post-transcriptional level by transfection of
muscle cells with antisense RNA. Essentially, 2'- O -methyl
oligoribonucleotides (2'OMeRNA) were delivered to the nuclei of primary mdx
myoblasts in culture. Dystrophin expression was observed in the sarcolemma
of transfected mdx myotubes after transfection by an oligonucleotide
complementary to the 3' splice site of murine dystrophin intron 22. Direct
sequencing of RT-PCR products from these cells revealed precise splicing of
exon 22 to exon 30, skipping the mutant exon and creating a novel in-frame
dystrophin transcript. As patients with comparable in- frame internal
deletions show relatively mild myopathic symptoms, this may in the future
offer a therapeutic approach for DMD, as well as for other inherited
disorders.
ARTICLES
Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides
Division of Biochemistry, Royal Holloway University of London, Egham TW20 0EX, UK. m.dunckley@rpms.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Jearawiriyapaisarn, H. M. Moulton, P. Sazani, R. Kole, and M. S. Willis Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers Cardiovasc Res, November 3, 2009; (2009) cvp335v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-O. Desmet, D. Hamroun, M. Lalande, G. Collod-Beroud, M. Claustres, and C. Beroud Human Splicing Finder: an online bioinformatics tool to predict splicing signals Nucleic Acids Res., May 1, 2009; 37(9): e67 - e67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yokota, S. Takeda, Q.-L. Lu, T. A. Partridge, A. Nakamura, and E. P. Hoffman A Renaissance for Antisense Oligonucleotide Drugs in Neurology: Exon Skipping Breaks New Ground Arch Neurol, January 1, 2009; 66(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Ivanova, A. Arzumanov, R. Abes, H. Yin, M. J. A. Wood, B. Lebleu, and M. J. Gait Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle Nucleic Acids Res., November 1, 2008; 36(20): 6418 - 6428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wu, H. M. Moulton, P. L. Iversen, J. Jiang, J. Li, J. Li, C. F. Spurney, A. Sali, A. D. Guerron, K. Nagaraju, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer PNAS, September 30, 2008; 105(39): 14814 - 14819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aartsma-Rus and G.-J. B. van Ommen Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications RNA, October 1, 2007; 13(10): 1609 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Denti, A. Rosa, G. D'Antona, O. Sthandier, F. G. De Angelis, C. Nicoletti, M. Allocca, O. Pansarasa, V. Parente, A. Musaro, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model PNAS, March 7, 2006; 103(10): 3758 - 3763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Soret, N. Bakkour, S. Maire, S. Durand, L. Zekri, M. Gabut, W. Fic, G. Divita, C. Rivalle, D. Dauzonne, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors PNAS, June 14, 2005; 102(24): 8764 - 8769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Mattick and I. V. Makunin Small regulatory RNAs in mammals Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R121 - R132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goyenvalle, A. Vulin, F. Fougerousse, F. Leturcq, J.-C. Kaplan, L. Garcia, and O. Danos Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping Science, December 3, 2004; 306(5702): 1796 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Selkirk Gene therapy in clinical medicine Postgrad. Med. J., October 1, 2004; 80(948): 560 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, M. Asparuhova, V. Brondani, I. Ziekau, T. Klimkait, and D. Schumperli Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A Nucleic Acids Res., July 14, 2004; 32(12): 3752 - 3759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ittig, S. Liu, D. Renneberg, D. Schumperli, and C. J. Leumann Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA Nucleic Acids Res., January 15, 2004; 32(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bertoni, C. Lau, and T. A. Rando Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping Hum. Mol. Genet., May 15, 2003; 12(10): 1087 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aartsma-Rus, A. A.M. Janson, W. E. Kaman, M. Bremmer-Bout, J. T. den Dunnen, F. Baas, G.-J. B. van Ommen, and J. C.T. van Deutekom Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients Hum. Mol. Genet., April 15, 2003; 12(8): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. De Angelis, O. Sthandier, B. Berarducci, S. Toso, G. Galluzzi, E. Ricci, G. Cossu, and I. Bozzoni Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells PNAS, July 9, 2002; 99(14): 9456 - 9461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kalbfuss, S. A. Mabon, and T. Misteli Correction of Alternative Splicing of Tau in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 J. Biol. Chem., November 9, 2001; 276(46): 42986 - 42993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Crawford, Q. L. Lu, T. A. Partridge, and J. S. Chamberlain Suppression of revertant fibers in mdx mice by expression of a functional dystrophin Hum. Mol. Genet., November 1, 2001; 10(24): 2745 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C.T. van Deutekom, M. Bremmer-Bout, A. A.M. Janson, I. B. Ginjaar, F. Baas, J. T. den Dunnen, and G.-J. B. van Ommen Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells Hum. Mol. Genet., July 1, 2001; 10(15): 1547 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Friedman, J. Kole, J. A. Cohn, M. R. Knowles, L. M. Silverman, and R. Kole Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides J. Biol. Chem., December 17, 1999; 274(51): 36193 - 36199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tyson, S. Malcolm, and M. Bitner-Glindzicz Splice Mutations in KVLQT1? Circulation, May 11, 1999; 99 (18): 2476 - 2479. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Lim and K. J. Hertel Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3' Splice Site Pairing J. Biol. Chem., November 21, 2001; 276(48): 45476 - 45483. [Abstract] [Full Text] [PDF]
|
|